Still Progressing on Keytruda® or Opdivo®? Gold Coast Patients May Qualify for Investigational Treatment

If You're Still Fighting on Keytruda® or Opdivo®, You're Not Out of Options Yet

You May Qualify If :

  • Diagnosed with NSCLC, melanoma, bladder/kidney cancer, or select GI cancers
  • Currently on immunotherapy such as Keytruda (pembrolizumab) or Opdivo (nivolumab)
  • Cancer is stable or progressing, according to your doctor
  • Able to manage light daily activities
Travel, meals, and accommodation fully covered

Quick Eligibility Check — Takes Less Than 3 Minutes

What This Study Tests

How do you keep fighting when the strongest therapies stop working?


This clinical trial is for adults with select cancers whose recent scans show their cancer is stable or growing while receiving Keytruda® or Opdivo®. Researchers are testing the investigational Hemopurifier® treatment together with current immunotherapy, at no additional cost to regular care.


The Hemopurifier® is a blood-filtering device designed to capture and remove extracellular vesicles — tiny messengers released by tumours that may help cancer hide and spread. By clearing them from the blood, researchers aim to lift barriers that keep immunotherapy from working at its best.


Participants may receive 3 Hemopurifier® sessions in a one-week period before their next scheduled dose of immunotherapy. Travel and lodging reimbursement is available.

Receive the investigational Hemopurifier® treatment together with your current immunotherapy (Keytruda® or Opdivo®), all at no additional costs to your regular care.

Help test a new approach that may strengthen how the immune system fights cancer.

Be reimbursed for travel and lodging.

Contribute to research that could improve treatment options and outcomes for future cancer patients.

Study Details and Location

1

2

3

4

A screening period

5-day treatment period with blood filtration

8 weekly follow-up visits

Follow-up visits at 6 and 12 months

Locations: Adelaide, Sydney, or Gold Coast research centers.

All travel, accommodation, and meal expenses reimbursed.

Meet the Lead Researcher

Dr. Marco Matos

Dr. Marco Matos is a senior Medical Oncologist on the Gold Coast, providing expert care for patients with solid organ malignancies. He earned his medical degree from the University of San Marcos in Peru and, after moving to Australia in 1996, completed a Master of Public Health at the University of New South Wales.

Pindara Private Hospital

Location: Allchurch Avenue, Benowa, QLD 4217

Lead Researcher: Dr. Marco Matos at Pindara Private Hospital

Ethics Committee: This study has been reviewed and approved by the Belberry Ethics Committee

Who Can Participate?

You may qualify if you are

  • An adult aged 18 and above who are diagnosed with one of these cancers:
    • Non-small cell lung cancer
    • Melanoma
    • Bladder or urinary tract cancer
    • Kidney cancer
    • Colorectal cancer (MSI-H or dMMR)
    • Stomach or gastr-oesophageal junction cancer
    • Oesophageal cancer
    • Head and neck cancer
    • Cervical cancer
    • Mesothelioma
  • Currently receiving treatment with Keytruda® (pembrolizumab) or Opdivo® (nivolumab), with recent scans showing the cancer is stable or growing.
  • Able to carry out normal activities with little or some limitations (such as doing light work or household tasks).
  • Willing to use effective birth control during the study and for about 4 months after (if applicable).
  • Able to attend the required study visits, including:
    • A screening period
    • Hemopurifier® treatment sessions before the next scheduled dose of immunotherapy one to three treatments (4 hour long treatments) over a 1 week period.
    • A safety follow-up visit 28 days later, and follow-up visits for up to 1 year.

You may not qualify if you

  • Have cancer that has spread to the brain or the lining around the brain
  • Have certain immune system conditions, autoimmune disorders requiring strong medications in the past year, or are being treated for non-infectious lung inflammation
  • Have tested positive for HIV, hepatitis B, or hepatitis C
  • Cannot take full blood-thinning treatments during the Hemopurifier treatment
  • Are currently pregnant, planning pregnancy, or breastfeeding
  • Have had an allergic reaction to heparin or a serious blood reaction called heparin-induced thrombocytopenia
  • Would not be willing to receive a blood transfusion if needed
  • Have had a solid organ transplant (such as kidney, liver, heart, or lung)
  • Are currently in another clinical trial
Qualified Health Professionals

Qualified Health Professionals

Qualified health professionals will monitor your health as it relates to the study.

IRB Approved

Ethics Approved

This trial has been reviewed & approved by an independent ethics committee. 

Trained Staff

Trained Staff

All research staff running this trial have been trained in GCP, which assures that the rights, safety, & well-being of research subjects are protected & respected.

Data Encrypted

Encrypted Data

All data you provide us is encrypted & stored safely & securely in accordance with security & privacy rules.

HIPPA Compliant

National Privacy Standards

We follow all established national privacy standards used in all doctors' offices, hospitals, & other businesses where personal medical information is stored.

Informed Consent Before Participation

You will receive a detailed outline of all details of the study, including treatment, risks, and procedures, and will be given the chance to ask questions to the study staff, before you decide whether to participate.

Withdraw At Any Time

If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.

Strictly Confidential

Your records relating to this study and any other information received will be kept strictly confidential, except as required by law.

Find Out if You Qualify Through a Quick, 3-Minute Check

© 2026 Trialfacts. All Rights Reserved. | (415) 704-1575 USA | (07) 3054 7094 AUS | support@trialfacts.com | Privacy Policy